Winter 2023, Zhejiang Coast
When Chen Lin’s eyelids turned dusky purple and angry red patches spread across her neck and fingers, she blamed allergies. The otherwise healthy 34-year-old got topical creams from dermatology and thought little of it—until dry coughs seized her chest. Soon, even short walks left her gasping. Work became impossible. She went to the hospital.

The diagnosis—anti-MDA5 dermatomyositis—meant nothing to her family. But the doctor’s grave expression said everything. When local treatment failed, he urged: "Go to Shanghai. Renji Hospital might save you." Survival odds were grim: historically, half of such patients didn’t live six months. An ambulance raced her to Shanghai.

January 2024
Amid holiday chaos, Renji’s rheumatology team fast-tracked her admission to their specialized ICU. Her oxygen levels had cratered to 75%—like climbing Everest without oxygen. Lab reports painted a dire picture: lungs riddled with inflammation, ferritin off the charts, immune cells vanishing. Then, COVID-19 entered the fray.

Doctors worked with urgent precision—ventilators, COVID antivirals, and a web of monitors. As consciousness faded, Chen Lin heard a calm voice cut through the beeping: "*Critical MDA5 dermatomyositis with COVID. Start aggressive anti-inflammatories and immunoadsorption. *"

Three weeks later
Hope flickered as numbers improved—then vanished when fever spiked and oxygen plummeted. A CT scan showed lungs whitened by inflammation. Bronchoscopy confirmed COVID was replicating wildly, fueling the fire in her muscles. The battle intensified: anti-viral versus the virus, targeted therapy versus the raging dermatomyositis.

ICU teams worked around the clock. "We’ll fight to the end," they told her family—now paralyzed by fear but clinging to faith: "We trust you." Miraculously, weeks turned into months. The ventilator came off. Her tracheostomy healed. By spring, she was sitting up, speaking.

During rounds, Chen Lin recognized the voice from her darkest hours: Professor Ye Shuang, head of rheumatology, whose decade-long quest to conquer MDA5 dermatomyositis had drawn a team of relentless innovators to his side.

Moving to a general ward, she heard stories of this pioneering rheumatology department—founded decades before others, built on a "*never turn a patient away" creed. Her three-month ICU stay had been powered by cutting-edge life support systems and immunotherapies—tools that had saved hundreds from diseases like lupus, dermatomyositis, and medical mysteries textbooks hadn’t named.

Three months after discharge
Chen Lin needed only occasional oxygen. At her 100-day checkup, a new CT scan revealed healed lungs. She’d never found lung tissue beautiful before—those twin black crescents meant life. In the waiting room, a headline caught her eye: "Renji Rheumatology: Where Rapid Response Meets Advanced Rescue—A Lifeline for Critical Cases."

A quiet smile surfaced. She’d stared death in the face here—and lived. "I’ll survive," she thought. "So will others. Because Renji fights with us."